Researchers from the University of California San Francisco have engineered a bioreactor apparatus utilizing laboratory-cultured human kidney cells to replicate essential kidney functions. This groundbreaking device has the potential to liberate individuals from the necessity of dialysis or the use of potent immunosuppressive drugs post-transplant.

During week-long trials in pigs, the scientists reported no apparent side effects or complications, signifying promising safety and efficacy. As detailed on the university's website, this innovative device operates inconspicuously, akin to a pacemaker, without provoking an immune system response in the recipient.

In the future, scientists intend to populate the bioreactor with various types of kidney cells responsible for critical functions such as maintaining fluid balance and secreting hormones to regulate blood pressure. This will be coupled with a blood-filtering device to complete the integrated system.

The objective is to develop a human-scale device that surpasses the limitations of dialysis, a life-sustaining but suboptimal treatment for individuals with kidney failure, as it does not replicate the full functionality of a natural organ. In the United States, over 500,000 individuals rely on dialysis several times a week, with many aspiring to secure kidney transplants. However, the scarcity of donors results in only about 20,000 transplants annually. An implantable artificial kidney would represent a significant advancement in addressing this shortfall.

The scientists designed the bioreactor to establish a direct connection with blood vessels and veins, facilitating the passage of nutrients and oxygen, much akin to the functioning of a transplanted kidney.

Silicon membranes serve as protective barriers, shielding the kidney cells within the bioreactor from potential attacks by the recipient's immune cells.

As a part of their experimentation, the team employed proximal tubule cells, specialized in regulating water and salt. Co-author H. David Humes, MD, from the University of Michigan, had previously utilized these cells to provide critical assistance to intensive care unit patients undergoing dialysis, yielding life-saving outcomes, as mentioned in the statement.